DOCSLIB.ORG

Making a Difference Our Mission Is to Foster and Promote Research with the Aim of Improving Human and Animal Health

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Making a Difference Our Mission Is to Foster and Promote Research with the Aim of Improving Human and Animal Health STRATEGIC PLAN 2005 –2010 MAKING A DIFFERENCE OUR MISSION IS TO FOSTER AND PROMOTE RESEARCH WITH THE AIM OF IMPROVING HUMAN AND ANIMAL HEALTH COVER Scanning electron micrograph of Penicillium mould, producing spores. D Gregory and D Marshall CONTENTS Foreword 2 From Sir Dominic Cadbury and Dr Mark Walport Introduction 4 Mission and strategic aims 6 Our priorities 8 Where our emphasis will lie during 2005–2010 Aim 1 Advancing knowledge 10 Aim 2 Using knowledge 12 Aim 3 Engaging society 14 Celebrating success 16 How we performed against the priorities we set in 2000 Aim 4 Developing people 18 Aim 5 Facilitating research 20 Aim 6 Developing our organisation 22 Financial framework 24 Our spending strategy for 2005–2010 Monitoring progress 26 How we will assess progress towards our goals Governors and senior staff 28 1 FOREWORD Since the Wellcome Trust’s formation in 1936 we have continuously supported excellent research, with the aim of improving human and animal health. We recognised then, as we do now, the need to provide long-term support, since most biomedical research is incremental, building on past achievements. During the period of our first five-year Plan, Planning for the Future, published in 2000, we achieved a great deal. Through our support for the Wellcome Trust Sanger Institute, we made a key contribution to the completion of the Human Genome Project. We worked in partnership with the UK Government to help revitalise university infrastructure and enhance clinical research. Our long-term support for our major overseas programmes has helped to improve understanding of diseases that have a devastating impact in developing countries. We also restructured our scientific programmes, refocused and enhanced our technology transfer activities, and took forward a broad range of imaginative activities to engage the public in biomedical science. Highlights of some of the exciting outcomes that came to fruition during the period of our last Plan are featured on the following pages. Our aims and objectives for 2005–2010 will ensure that we continue to make a difference in the areas we support. In particular, we will retain the flexibility to respond rapidly to the best ideas from our communities, and provide the most appropriate form of support to take these ideas forward. We will build on the success of our international funding, continue to engage public audiences, and develop new initiatives to facilitate and accelerate the take-up of research outcomes by clinicians, industry and policy makers. The success of this Plan will depend critically on the wide range of people and organisations with whom we work. The most important are the researchers and institutions who carry out the research that we support. Additionally, our staff, and the experts from around the world who review applications and serve on our advisory committees, will play a crucial role in taking forward this Plan. Many of the challenges we are seeking to address will not be realised by one organisation working alone. In implementing this Plan, we will actively seek to work in partnership with other organisations where added benefit can be gained, building on the wide range of innovative funding partnerships we have brokered over recent years. This Plan will be used as a basis upon which we will identify and develop strategic priorities, informed by ideas from our communities. We will also use this Plan to set in place improved systems to assess our progress, so that we can ensure that we really are making a difference. Sir Dominic Cadbury Mark Walport CHAIRMAN DIRECTOR 2 STRATEGIC PLAN 2005–2010 FOREWORD FOREWORD STRATEGIC PLAN 2005–2010 3 RIGHT The Wellcome The Wellcome Trust is the most Trust Sanger Institute at Hinxton. diverse biomedical research charity FAR RIGHT The Wellcome Trust’s founder, Sir Henry in the world, supporting a spectrum Wellcome. BELOW A three-day-old of activity from basic science to human embryo. history of medicine Y Nikas INTRODUCTION Our independence and size enable us to act responsively and flexibly, seizing new opportunities and acting as a catalyst for innovation. We are able to take a long-term view and to take funding risks, acting for the public good. We are a major funder of research in the UK, with a strong international presence as well. For many of our activities we work with a wide range of partners. We fund excellence and encourage innovation by endeavouring to support the best researchers, the best teams and the best ideas. We support the Wellcome Trust Sanger Institute – a world-leading centre exploring the role of genomes in health and disease. In November 2000 we published our first five-year Plan, Planning for the Future. In the last five years, we have spent £2.4 billion in delivering our mission. At any one time, we support over 3000 researchers in more than 40 countries. Over the past five years, about 90 per cent of our funding has been in the UK. Most of the remaining 10 per cent supports research and capacity building in developing and restructuring countries. Our Strategic Plan for 2005–2010, Making a Difference, provides the context and direction for the Wellcome Trust during this period. We will update the Plan, periodically, at www.wellcome.ac.uk. 4 STRATEGIC PLAN 2005–2010 INTRODUCTION WELLCOME TRUST SANGER INSTITUTE WELLCOME TRUST Forming part of the Wellcome To accommodate the expanded The Wellcome Trust was created Trust Genome Campus at research programme at the Sanger on the death of Sir Henry Hinxton in Cambridgeshire, Institute, the £95 million South Wellcome in 1936. In 1880, Henry UK, the Wellcome Trust Sanger Field Project was completed in Wellcome and his partner Silas Institute is one of the world’s 2005 – providing new laboratories, Mainville Burroughs established foremost centres for genomics a data centre, research support a pharmaceutical company, and bioinformatics research. facilities and offices. Burroughs Wellcome & Co. Established in 1993, the Sanger In 1895, Silas Burroughs died, In addition to the Sanger Institute, Institute played a leading role leaving the company in the the Genome Campus houses the in the international Human hands of his partner. The firm European Bioinformatics Institute Genome Project – delivering flourished under Henry Wellcome’s (EBI). The Wellcome Trust has one-third of the human genome leadership. In his will, Wellcome committed to work with the UK sequence (the largest single vested the entire share capital of Research Councils to create space contribution). It has also the drug company, The Wellcome for an expansion to this vital sequenced the genomes of many Foundation Limited, in a charitable research institute. medically important pathogenic trust – the Wellcome Trust. organisms – including the agents The Genome Campus is also In the 1980s and 1990s, we that cause malaria, tuberculosis home to the Wellcome Trust diversified our asset base, selling and typhoid fever. Conference Centre – a high- shares in the Wellcome drug quality venue for major During the period of the Wellcome company and investing the international scientific meetings Trust’s last Plan, we funded a proceeds. The diversified portfolio and conferences. Through its £300 million five-year programme of investment assets is around Advanced Courses programme, of research at the Institute. Under £11 billion (as of June 2005). the Wellcome Trust has utilised the leadership of Allan Bradley, the unique facilities available the current Director, the focus on the Genome Campus to of the Institute has shifted from provide hands-on training in sequencing genomes to using the latest research techniques sequence data to answer important for hundreds of scientists from biological questions on the role around the world. of genes in health and disease. INTRODUCTION STRATEGIC PLAN 2005–2010 5 RIGHT Electron micrograph Our mission is to foster of a blood vessel that has grown into and promote research a melanoma. K Hodivala-Dilke with the aim of improving and M Stone human and animal health MISSION AND STRATEGIC AIMS MISSION AND STRATEGIC Over the next five years, our aims will be: Advancing knowledge: To support research Developing people: To foster a research community 1 to increase understanding of health and disease, 4 and individual researchers who can contribute and its societal context to the advancement and use of knowledge Using knowledge: To support the development Facilitating research: To promote the best 2 and use of knowledge to create health benefit 5 conditions for research and the use of knowledge Engaging society: To engage with society Developing our organisation: To use our resources 3 to foster an informed climate within which 6 efficiently and effectively. biomedical research can flourish. The UK will remain the principal base for our research activity. Assuming that the current investment climate remains unchanged, we aim to commit £1.5 billion in the UK over the next five years. We will also continue to fund internationally, and expect that this element of our funding will increase. 6 STRATEGIC PLAN 2005–2010 MISSION AND STRATEGIC AIMS Our strategic aims. Developing people Facilitating research Developing our organisation MISSION AND STRATEGIC AIMS STRATEGIC PLAN 2005–2010 7 RIGHT This Plan sets the direction we aim Colony of Gloeotrichia, a cyanobacterium. to follow and outlines how we will M I Walker LEFT (FROM TOP) Osteoporotic bone. identify and develop priorities across D Gregory and D Marshall A premature baby. our activities Child from Kilifi, where part of our Kenyan research
Load more

Recommended publications
  • ANNUAL REVIEW 1 October 2005–30 September
    WELLCOME TRUST ANNUAL REVIEW 1 October 2005–30 September 2006 ANNUAL REVIEW 2006 The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. It funds innovative biomedical research, in the UK and internationally, spending around £500 million each year to support the brightest scientists with the best ideas. The Wellcome Trust supports public debate about biomedical research and its impact on health and wellbeing. www.wellcome.ac.uk THE WELLCOME TRUST The Wellcome Trust is the largest charity in the UK and the second largest medical research charity in the world. 123 CONTENTS BOARD OF GOVERNORS 2 Director’s statement William Castell 4 Advancing knowledge Chairman 16 Using knowledge Martin Bobrow Deputy Chairman 24 Engaging society Adrian Bird 30 Developing people Leszek Borysiewicz 36 Facilitating research Patricia Hodgson 40 Developing our organisation Richard Hynes 41 Wellcome Trust 2005/06 Ronald Plasterk 42 Financial summary 2005/06 Alastair Ross Goobey 44 Funding developments 2005/06 Peter Smith 46 Streams funding 2005/06 Jean Thomas 48 Technology Transfer Edward Walker-Arnott 49 Wellcome Trust Genome Campus As at January 2007 50 Public Engagement 51 Library and information resources 52 Advisory committees Images 1 Surface of the gut. 3 Zebrafish. 5 Cells in a developing This Annual Review covers the 2 Young children in 4 A scene from Y fruit fly. Wellcome Trust’s financial year, from Kenya. Touring’s Every Breath. 6 Data management at the Sanger Institute. 1 October 2005 to 30 September 2006. CONTENTS 1 45 6 EXECUTIVE BOARD MAKING A DIFFERENCE Developing people: To foster a Mark Walport The Wellcome Trust’s mission is research community and individual Director to foster and promote research with researchers who can contribute to the advancement and use of knowledge Ted Bianco the aim of improving human and Director of Technology Transfer animal health.
    [Show full text]
  • CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4
    CRISPR and Beyond Perturbations at Scale to Understand Genomes 2-4 September 2019 Wellcome Genome Campus, UK Lectures to be held in the Francis Crick Auditorium Lunch and dinner to be held in the Hall Restaurant Poster sessions to be held in the Conference Centre Spoken presentations - If you are an invited speaker, or your abstract has been selected for a spoken presentation, please give an electronic version of your talk to the AV technician. Poster presentations – If your abstract has been selected for a poster, please display this in the Conference Centre on arrival. Conference programme Monday, 2 September 2019 11:45-12:50 Registration 12:50-13:00 Welcome and introductions Leopold Parts, Wellcome Sanger Institute UK 13.00-14.00 Keynote lecture Allan Bradley Kymab, UK 14:00-15:30 Session 1: Understanding impact of coding variations Chair: Leopold Parts, Wellcome Sanger Institute UK 14:00 New approaches for addressing the effect of genetic variation at scale Douglas Fowler University of Washington, USA 14:30 Tools for systematic proactive functional testing of human missense variants Frederick Roth University of Toronto 15:00 The mutational landscape of a prion-like domain Benedetta Bolognesi Institute for Bioengineering of Catalonia, Spain 15:15 Functional determination of all possible disease-associated variants in a region of CARD11 using saturation genome editing Richard James University of Washington, USA 15:30-16:00 Afternoon tea 16:00-17:30 Session 2: Measuring consequences of non-coding variation Chair: Lea Starita, University
    [Show full text]
  • Strategic Plan 2011-2016
    Strategic Plan 2011-2016 Wellcome Trust Sanger Institute Strategic Plan 2011-2016 Mission The Wellcome Trust Sanger Institute uses genome sequences to advance understanding of the biology of humans and pathogens in order to improve human health. -i- Wellcome Trust Sanger Institute Strategic Plan 2011-2016 - ii - Wellcome Trust Sanger Institute Strategic Plan 2011-2016 CONTENTS Foreword ....................................................................................................................................1 Overview .....................................................................................................................................2 1. History and philosophy ............................................................................................................ 5 2. Organisation of the science ..................................................................................................... 5 3. Developments in the scientific portfolio ................................................................................... 7 4. Summary of the Scientific Programmes 2011 – 2016 .............................................................. 8 4.1 Cancer Genetics and Genomics ................................................................................ 8 4.2 Human Genetics ...................................................................................................... 10 4.3 Pathogen Variation .................................................................................................. 13 4.4 Malaria
    [Show full text]
  • Fiona Fox Chief ExecuVe
    Fiona Fox Chief Execu+ve Set up in 2002 aer things went very wrong: - MMR & au;sm - GM crops - BSE - Animal research AIMS Vision Policy decisions and public debate informed by accurate, evidence-based scien7fic informaon in the news media Mission To make it easier for journalists to access the best science when stories hit the headlines and to ensure that more scien7sts engage with the media when stories hit the headlines Values Reliable, fast, accurate, authoritave, independent, media savvy SMC Philosophy " We’ll get the media to ‘DO’ science better when scientists ‘DO’ media better " Animal research in the UK media 1. The Bad Old Days Reac;ng to animal extremism 1980s – 1990s - Almost every story is on extremism - Only a handful of scien;sts prepared to speak out - Animal research covered by general and polical reporters - Funders and government stay quiet Legislave, judicial & Animal ac;vist / extremist ac;vity Science & medical governmental acon community acon 1997 (July) Consort Kennels in Hereford, a laboratory beagle breeder, closes aer a 10-month animal rights campaign including the theG of 26 beagles. 1999 (August) Hillgrove Farm in Oxfordshire, the UK's only commercial breeder of laboratory cats, closes aer a violent three year campaign. (Jan) Cambridge University abandons plan 2004 for new primate laboratory aer intense campaigning. (Oct) Darley Oaks Farm in Staffordshire closes its guinea pig breeding business aer a violent six-year campaign including digging up the grave of Gladys Hammond, the owners’ mother-in-law, sparking
    [Show full text]
  • 158273472.Pdf
    ANNUAL .2003REPCOLD SPRING HARBOR LABORATORY .1; ANNUAL REPORT 2003 © 2004 by Cold Spring Harbor Laboratory Cold Spring Harbor Laboratory One Bungtown Road Cold Spring Harbor, New York 11724 Web Site: www.cshl.edu Managing Editors Jeff Picarello, Lisa Becker Production Editor Rena Steuer Copy Editor Dorothy Brown Development Manager Jan Argentine Project Coordinators Maria Falasca, Nora Rice Production Manager Denise Weiss Desktop Editor Susan Schaefer Nonscientific Photography Miriam Chua, Bill Geddes Cover Designer Denise Weiss Book Designer Emily Harste Front cover: McClintock Laboratory (right) and Carnegie Library (left) (photos by Miriam Chua) Back cover: Magnolia Kobus on grounds of Cold Spring Harbor Laboratory (photo by Bruce Stillman) Section title pages: Miriam Chua Contents Officers of the Corporation/Board of Trusteesiv-v Governancevi Committees vii Edwin Marks (1926-2003) viii PRESIDENT'S REPORT Highlights5 CHIEF OPERATING OFFICER'S REPORT 25 50TH ANNIVERSARY OF THE DOUBLE HELIX 29 RESEARCH 47 Cancer: Gene Expression 49 Cancer: Genetics 74 Cancer: Cell Biology 106 Bioinformatics and Genomics 134 Neuroscience152 Plant Development and Genetics 199 CSHL Fellows 212 Author Index 217 WATSON SCHOOL OF BIOLOGICAL SCIENCES 219 Dean's Report 221 Courses 238 Undergraduate Research Program245 Partners for the Future 248 Nature Study 249 COLD SPRING HARBOR LABORATORY MEETINGS AND COURSES 251 Academic Affairs253 Symposium on Quantitative Biology 255 Meetings 258 Postgraduate Courses295 Seminars 353 BANBURY CENTER 355 Director's Report357 Meetings 365 DOLAN DNA LEARNING CENTER 403 Director's Report 405 Workshops, Meetings, and Collaborations 418 COLD SPRING HARBOR LABORATORY PRESS 425 Publications 426 Executive Director's Report 427 FINANCE 431 History of the CSHL Endowment 433 Financial Statements 444 Financial Support448 Grants448 Institutional Advancement 457 Capital and Program Contributions 458 Watson School of Biological Sciences Capital Campaign 459 Annual Contributions 460 LABORATORY STAFF 474 III Officers of the Corporation William R.
    [Show full text]
  • Human Genetics 1990–2009
    Portfolio Review Human Genetics 1990–2009 June 2010 Acknowledgements The Wellcome Trust would like to thank the many people who generously gave up their time to participate in this review. The project was led by Liz Allen, Michael Dunn and Claire Vaughan. Key input and support was provided by Dave Carr, Kevin Dolby, Audrey Duncanson, Katherine Littler, Suzi Morris, Annie Sanderson and Jo Scott (landscaping analysis), and Lois Reynolds and Tilli Tansey (Wellcome Trust Expert Group). We also would like to thank David Lynn for his ongoing support to the review. The views expressed in this report are those of the Wellcome Trust project team – drawing on the evidence compiled during the review. We are indebted to the independent Expert Group, who were pivotal in providing the assessments of the Wellcome Trust’s role in supporting human genetics and have informed ‘our’ speculations for the future. Finally, we would like to thank Professor Francis Collins, who provided valuable input to the development of the timelines. The Wellcome Trust is a charity registered in England and Wales, no. 210183. Contents Acknowledgements 2 Overview and key findings 4 Landmarks in human genetics 6 1. Introduction and background 8 2. Human genetics research: the global research landscape 9 2.1 Human genetics publication output: 1989–2008 10 3. Looking back: the Wellcome Trust and human genetics 14 3.1 Building research capacity and infrastructure 14 3.1.1 Wellcome Trust Sanger Institute (WTSI) 15 3.1.2 Wellcome Trust Centre for Human Genetics 15 3.1.3 Collaborations, consortia and partnerships 16 3.1.4 Research resources and data 16 3.2 Advancing knowledge and making discoveries 17 3.3 Advancing knowledge and making discoveries: within the field of human genetics 18 3.4 Advancing knowledge and making discoveries: beyond the field of human genetics – ‘ripple’ effects 19 Case studies 22 4.
    [Show full text]
  • 09889 MRC Network News.Qxp
    network Winter 2005/06 News, views and information from the Medical Research Council In this issue £10m boost for flu research MRC College of Experts The Medical Research Council is set to increase funding of research into influenza Promoting scientific and other emerging infections by £10m. In excellence now and in late November 2005, it put out a call for the future proposals to enhance research to tackle page 2 emerging infections with a pandemic potential. The extra money comes on top Basic thinking of the £1.6m that the MRC had already spent on influenza research in 2005. A look at the importance of This recognition that extra funds for flu fundamental science to research were needed was prompted by a human health mission of MRC experts to Vietnam and page 4 China last October, led by Professor Andrew McMichael, chair of the MRC’s Discussions in progress during an MRC international flu workshop in Infections and Immunity Board.The team London, December 2005 Andrew StuartPhotograph by MRC wanted to discover more about the spread international of the avian flu virus and to discuss how The mission also visited several institutes in MRC scientists lead collaboration between the UK, China and Vietnam China, where biomedical research capacity is could be improved in the future. It also included growing quickly. Professor McMichael said: mission to China in Sir John Skehel – whose work at the MRC “They’re investing heavily in basic research and October 2005 National Institue for Medical Research has want to translate the findings into new
    [Show full text]
  • The Changing Governance of Genetic Intervention Technologies
    The Changing Governance of Genetic Intervention Technologies An Analysis of Legal Change Patterns, Drivers, Impacts, and a Proposed Reform Neil Harrel Thesis submitted to the University of Ottawa in partial fulfillment of the requirements for the Doctorate in Philosophy (Ph.D.) degree in Law Faculty of Law University of Ottawa © Neil Harrel, Ottawa, Canada, 2021 . Abstract Major breakthroughs in biotechnology are leading to the emergence of novel methods to select and alter future individuals’ genomes. Genetic intervention technology is evolving from the medical practice of screening for life-threatening congenital malformations to the selection against embryos that might develop mild disabilities. Scientific research suggests that heritable genome-editing technology would enable the custom alteration and the enhancement of human biological characteristics, including appearance, athletic and intellectual abilities. These novel developments and their potential long-term impacts raise the question of how effective are the laws on genetic interventions in setting limits to rapidly evolving biotechnologies. This thesis examines genetic intervention laws in the United Kingdom and France and shows it exhibits a pattern of continuous legal changes over the past several years to permit a broadening range of genetic interventions that were previously prohibited. This pattern is characterized by the regulatory licensing of genetic interventions that specific legal restrictions have sought to disallow, such as screening against conditions that are mild, treatable and not predominantly determined by genes. Moreover, governments are currently considering replacing their bans on inheritable human genetic modification with regulations that will allow the alteration of genes linked to conditions deemed “serious” and for “therapeutic” purposes. This proposed regulatory model would enable licensing the very same type of genomic alterations intended to be prohibited – genetic enhancements of human physiological and cognitive capabilities.
    [Show full text]
  • Sharing Our Practice: Successes and Challenges of Public Engagement in the Wellcome Trust’S UK Centres
    Public engagement workshop report Sharing Our Practice: Successes and challenges of public engagement in the Wellcome Trust’s UK Centres 14 May 2013 Sharing Our Practice: Successes and challenges of public engagement in the Wellcome Trust’s UK centres Report of a one-day workshop held at the Wellcome Trust, London, 14 May 2013 Executive summary Public engagement is one of the Wellcome Trust’s key objectives, and its major UK biomedical science and medical humanities centres are expected to deliver programmes of public-facing work alongside their research. Several centres have established extensive and varied programmes of outreach work. Sharing experiences can encourage good practice and stimulate discussion on issues that are common to different centres. The choice of audience remains fundamental to successful public engagement, and a wide variety of audiences are currently being engaged by our centres. Many activities focus on engaging with schools, although several centres are attempting to increase their engagement with adult audiences. Understanding audiences, for example through consultation and dialogue, can shape the nature of an engagement project and the formats used. Consultation can also provide the basis of an integrated evaluation, which would ideally be developed at the beginning of a project. Addressing topical issues can be a powerful way to engage with audiences, but dealing with controversial topics requires careful preparation. In particular, the way to address the use of animals in research needs to be considered carefully. Patient groups are an attractive potential audience because they are likely to have a strong intrinsic interest in research. Connecting with patients offers opportunities for dialogue that benefits research, as well as patients.
    [Show full text]
  • Wellcome Trust Annual Report and Financial Statements 2009
    ANNUAL REPORT AND FINANCIAL STATEMENTS 2009 A charity registered in England, no. 210183. 1 TABLE OF CONTENTS Page Chairman’s Statement 2 Trustee’s Report 4 Objects, Mission and Aims 4 Financial Summary 5 Review of Past and Future Activities 7 Investment Summary 10 Remuneration Report 19 Structure, Governance and Policy 21 Independent Auditors’ Report 28 Consolidated Statement of Financial Activities 29 Consolidated Balance Sheet 30 Statement of Financial Activities of the Trust 31 Balance Sheet of the Trust 32 Consolidated Cash Flow Statement 33 Notes to the Financial Statements 34 Reference and Administrative Details 73 2 CHAIRMAN’S STATEMENT In February 2009 I had the great privilege of spending majority of those attending the continuing professional time with colleagues at our Major Overseas Programme in development courses at the Centre have indicated Vietnam. Based in the Hospital for Tropical Diseases, Ho the experience had a significant positive impact on Chi Minh City, researchers are improving our understanding themselves, their school or their pupils, and many say of many of the world’s deadliest diseases, including malaria, they have developed new skills in teaching methods. dengue, typhoid, tetanus and tuberculosis. It is a sobering experience to witness first hand the debilitating effects of Expenditure and investments diseases that we do not see in our day to day lives. In the clinical wards we visited, the important and integral role that The many exciting projects outlined in our Trustee’s research plays in improving patient care and quality of life Report would not be possible without the privilege of for so many individuals and their families is abundantly clear.
    [Show full text]
  • Paterson Institute for Cancer Research SCIENTIFIC REPORT 2006 Leukapheresis Blood Product Is Depleted of CD25 + Lymphocytes Prior to Infusion Back Into the Patient
    Paterson Institute for Cancer Research SCIENTIFIC REPORT 2006 Leukapheresis blood product is depleted of CD25 + lymphocytes prior to infusion back into the patient. CD4 +CD25 + regulatory T-cells are thought to be instrumental in allowing a growing cancer to evade immunological attack and the rationale behind this clinical trial is that their removal may unmask an anti-tumour immune response in patients with cancer (See Biological Immune and Gene Therapy Group report on page 36) . Illustration Credits Many illustrations in this report were taken by Jenny Varley and Paul Cliff Cancer Research UK Paterson Institute for Cancer Research SCIENTIFIC REPORT 2006 Cancer Research UK Paterson Institute for Cancer Research Scientific Report 2006 Edited by Professor Jenny Varley, Assistant Director (Research) Design & Layout by Mark Wadsworth (Web & Graphic Designer) Paterson Institute for Cancer Research Wilmslow Road, Manchester M20 4BX Tel: 0161 446 3156 http://www.paterson.man.ac.uk ISSN 1740-4525 Copyright © 2006 Cancer Research UK Printed by Paramount Print Cancer Research UK Registered Charity No. 1089464 Registered as a company limited by guarantee in England and Wales No. 4325234 Registered address 61 Lincoln’s Inn Fields, London WC2A 3PX Tel +44 (0) 20 7242 0200 http://www.cancerresearchuk.org Contents Director’s Introduction . 6 The Manchester Cancer Research Centre. 8 The Paterson Institute for Cancer Research Bioinformatics Group ........................................................................ Crispin Miller . 10 Carcinogenesis
    [Show full text]
  • Working with Schools in STEM Public Engagement Guidelines for Research Centres July 2013
    Public Engagement Working with Schools in STEM Public Engagement Guidelines for research centres July 2013 Improving School Governance | 1 Contents Acknowledgements 3 Purpose of the guidelines 4 Getting started 5 What are the key elements for adopting a strategic approach? 8 How do you make things happen? 12 Reviewing achievements 18 Sources of support and advice 19 2 Acknowledgements These guidelines would not have been possible without the support and cooperation of the staff of the Wellcome Trust-funded research centres (who willingly gave their time for interviews and visits to the centres), teacher interviewees, and the staff in the Medical Humanities and Engagement division of the Wellcome Trust. All their help and their contributions are very much appreciated. 3 Purpose of the guidelines “We will expect all of our major research groups to engage with the public about their work and will offer them support and training to do so.” Wellcome Trust Strategic Plan 2010–2020 Efforts to engage the wider public with science, technology, engineering and maths (STEM) have increased significantly in recent years. Many organisations aim their activities at young people to generate interest in STEM subjects and careers in STEM-related occupations. An obvious route to this audience is establishing ongoing relationships with schools. These guidelines arise from a study of current practice in 11 Wellcome Trust-funded research centres.1 Across the centres there is a great deal of good activity occurring with schools, and the overall commitment to this work is high. The purpose of these guidelines is to support the research centres, and other organisations, in improving the quality, quantity and range of activities they provide.
    [Show full text]